A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating The Safety And Efficacy Of Two Doses Of Simufilam In Subjects With Mild-To-Moderate Alzheimer's Disease

Grants and Contracts Details

StatusActive
Effective start/end date5/9/222/14/25

Funding

  • Premier Research International LLC: $108,349.00